The triple combination of Zalypsyis, bortezomib and dexamethasone triggers cell death, mainly through a synergistic induction of DNA damage and the blockade of NF-κB activation.

Multiple Myeloma treatment

Triple combination

Zalypsyis
Bortezomib
Dexamethasone

Double combinations

Zalypsyis
Bortezomib
Dexamethasone

Zalypsyis
Bortezomib
Dexamethasone

Zalypsyis
Bortezomib
Dexamethasone

Zalypsyis
Bortezomib
Dexamethasone

in vitro, ex vivo and in vivo experiments

- strong synergy
- higher efficacy

Trigger of cell death

- blockade of NF-κB activation
- synergistic induction of DNA damage

López-Iglesias et al., Haematologica, 2016